Genetics and molecular biology of mesothelioma

Recent Results in Cancer Research

Volumn 189, Issue , 2011, Pages 149-167

  Fennell, Dean A ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 METHOXYETHOXY) 2 METHYL 3 (2 PYRAZINYLMETHYL)NAPHTHO[2,3 D]IMIDAZOLE 4,9 DIONE; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANTINEOPLASTIC AGENT; AT 406; BETA CATENIN; CISPLATIN; ESTROGEN RECEPTOR BETA; HISTONE DEACETYLASE INHIBITOR; INHIBITOR OF APOPTOSIS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MERLIN; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEASOME INHIBITOR; PROTEIN KINASE B; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA; TL 32711; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; WNT PROTEIN; XAV 939;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENETICS; CANCER INHIBITION; CARCINOGENESIS; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; EPIGENETICS; GENE DISRUPTION; GENE EXPRESSION REGULATION; GENE LOSS; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; MALIGNANT TRANSFORMATION; MESOTHELIOMA; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CHROMOSOME ABERRATIONS; GENES, TUMOR SUPPRESSOR; HEPATOCYTE GROWTH FACTOR; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LOSS OF HETEROZYGOSITY; MESOTHELIOMA; NEUROFIBROMIN 2; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; WNT PROTEINS;

EID: 79955031861     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-10862-4_9     Document Type: Article

References (153)

1. Altomare DA, Vaslet CA, Skele KL, De Rienzo A, Devarajan K, Jhanwar SC, McClatchey AI, Kane AB, Testa JR (2005) A mouse model recapitulating molecular features of human mesothelioma. Cancer Res 65(18):8090-8095 (Pubitemid 41330570)
2. Altomare DA, You H, Xiao GH, Ramos-Nino ME, Skele KL, De Rienzo A, Jhanwar SC, Mossman BT, Kane AB, Testa JR (2005) Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 24(40):6080-6089 (Pubitemid 43080058)
3. Andujar P, Wang J, Descatha A, Galateau-Salle F, Abd-Alsamad I, Billon-Galland MA, Blons H, Clin B, Danel C, Housset B et al (2010) p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos. Lung Cancer (Amsterdam, Netherlands 67(1):23-30
4. Antonsson B, Conti F, Ciavatta A, Montessuit S, Lewis S, Martinou I, Bernasconi L, Bernard A, Mermod JJ, Mazzei G et al (1997) Inhibition of Bax channel-forming activity by Bcl-2. Science (New York) 277(5324):370-372 (Pubitemid 27450709)
5. Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A, Beneduce G, De Rosa V, Izzo F, Melucci MT et al (2005) Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 23(30):7660-7668 (Pubitemid 46291831)
6. Barbone D, Yang TM, Morgan JR, Gaudino G, Broaddus VC (2008) Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J Biol Chem 283(19):13021-13030
7. Batistatou A, Kyzas PA, Goussia A, Arkoumani E, Voulgaris S, Polyzoidis K, Agnantis NJ, Stefanou D (2006) Estrogen receptor beta (ERbeta) protein expression correlates with BAG-1 and prognosis in brain glial tumours. J Neurooncol 77(1):17-23 (Pubitemid 43870557)
8. Batra S, Shi Y, Kuchenbecker KM, He B, Reguart N, Mikami I, You L, Xu Z, Lin YC, Clement G et al (2006) Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. Biochem Biophys Res Commun 342(4):1228-1232
9. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M et al (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463(7283):899-905
10. Boldin MP, Goncharov TM, Goltsev YV, Wallach D (1996) Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 85(6):803-815
11. Borczuk AC, Cappellini GC, Kim HK, Hesdorffer M, Taub RN, Powell CA (2007) Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors. Oncogene 26(4):610-617 (Pubitemid 46160974)
12. Bosco EE, Nakai Y, Hennigan RF, Ratner N, Zheng Y (2010) NF2-deficient cells depend on the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhibition of proliferation. Oncogene 29(17):2540-2549
13. Bowles TL, Kim R, Galante J, Parsons CM, Virudachalam S, Kung HJ, Bold RJ (2008) Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase. Int J Cancer 123(8):1950-1955
14. Calvo R, West J, Franklin W, Erickson P, Bemis L, Li E, Helfrich B, Bunn P, Roche J, Brambilla E et al (2000) Altered HOX and WNT7A expression in human lung cancer. Proc Natl Acad Sci USA 97(23):12776-12781
15. Candido EP, Reeves R, Davie JR (1978) Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 14(1):105-113 (Pubitemid 8340438)
16. Cao XX, Mohuiddin I, Ece F, McConkey DJ, Smythe WR (2001) Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am J Respir Cell Mol Biol 25(5):562-568 (Pubitemid 33087106)
17. Cao X, Littlejohn J, Rodarte C, Zhang L, Martino B, Rascoe P, Hamid K, Jupiter D, Smythe WR (2009) Up-regulation of Bcl-xl by hepatocyte growth factor in human mesothelioma cells involves ETS transcription factors. Am J Pathol 175(5):2207-2216
18. Carlisi D, Lauricella M, D'Anneo A, Emanuele S, Angileri L, Di Fazio P, Santulli A, Vento R, Tesoriere G (2009) The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation. Eur J Cancer 45(13): 2425-2438
19. Center R, Lukeis R, Dietzsch E, Gillespie M, Garson OM (1993) Molecular deletion of 9p sequences in non-small cell lung cancer and malignant mesothelioma. Genes Chromosomes Cancer 7(1):47-53 (Pubitemid 23141740)
20. Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW, Wei S, Hao W, Kilgore J, Williams NS et al (2009) Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 5(2):100-107
21. Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee WC, Altomare DA, Nobori T, Olopade OI, Buckler AJ, Testa JR (1994) p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 54(21):5547-5551
22. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM (1995) FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81(4):505-512
23. Christensen BC, Houseman EA, Godleski JJ, Marsit CJ, Longacker JL, Roelofs CR, Karagas MR, Wrensch MR, Yeh RF, Nelson HH et al (2009) Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. Cancer Res 69(1):227-234
24. Cory S, Adams JM (2005) Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell 8(1):5-6 (Pubitemid 40991809)
25. Crisanti MC, Wallace AF, Kapoor V, Vandermeers F, Dowling ML, Pereira LP, Coleman K, Campling BG, Fridlender ZG, Kao GD et al (2009) The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther 8(8):2221-2231
26. Delage B, Fennell DA, Nicholson L, McNeish I, Lemoine NR, Crook T, Szlosarek PW (2010) Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer 126(12):2762-2772
27. Du C, Fang M, Li Y, Li L, Wang X (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102(1):33-42
28. Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA (2002) Pegylated arginine deiminase (ADI-SS PEG20, 000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res 62(19):5443-5450
29. Falleni M, Pellegrini C, Marchetti A, Roncalli M, Nosotti M, Palleschi A, Santambrogio L, Coggi G, Bosari S (2005) Quantitative evaluation of the apoptosis regulating genes Survivin, Bcl-2 and Bax in inflammatory and malignant pleural lesions. Lung Cancer (Amsterdam, Netherlands) 48(2):211-216
30. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917-921 (Pubitemid 40559006)
31. Fennell DA, Rudd RM (2004) Defective coreapoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development. Lancet Oncol 5(6):354-362 (Pubitemid 38684407)
32. Fennell DA, Gaudino G, O'Byrne KJ, Mutti L, van Meerbeeck J (2008) Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract 5(3):136-147
33. Fennell DA, Chacko A, Mutti L (2008) BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene 27(9):1189-1197 (Pubitemid 351294694)
34. Fernandez Y, Verhaegen M, Miller TP, Rush JL, Steiner P, Opipari AW Jr, Lowe SW, Soengas MS (2005) Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res 65(14):6294-6304 (Pubitemid 40994415)
35. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP (1999) Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401(6749):188-193 (Pubitemid 29436325)
36. Fischer JR, Ohnmacht U, Rieger N, Zemaitis M, Stoffregen C, Kostrzewa M, Buchholz E, Manegold C, Lahm H (2006) Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer (Amsterdam, Netherlands) 54(1):109-116
37. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ et al (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123-134
38. Fotheringham S, Epping MT, Stimson L, Khan O, Wood V, Pezzella F, Bernards R, La Thangue NB (2009) Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell 15(1):57-66
39. Fox S, Dharmarajan A (2006) WNT signaling in malignant mesothelioma. Front Biosci 11: 2106-2112 (Pubitemid 43822544)
40. Frizelle SP, Grim J, Zhou J, Gupta P, Curiel DT, Geradts J, Kratzke RA (1998) Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene 16(24):3087-3095 (Pubitemid 28318779)
41. Frizelle SP, Rubins JB, Zhou JX, Curiel DT, Kratzke RA (2000) Gene therapy of established mesothelioma xenografts with recombinant p16INK4a adenovirus. Cancer Gene Ther 7(11):1421-1425
42. Garber K (2009) Drugging the Wnt pathway: problems and progress. J Natl Cancer Inst 101(8):548-550
43. Gordon GJ, Appasani K, Parcells JP, Mukhopadhyay NK, Jaklitsch MT, Richards WG, Sugarbaker DJ, Bueno R (2002) Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma. Carcinogenesis 23(6): 1017-1024 (Pubitemid 34752958)
44. Gordon GJ, Mani M, Mukhopadhyay L, Dong L, Edenfield HR, Glickman JN, Yeap BY, Sugarbaker DJ, Bueno R (2007) Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma. J Pathol 211(4):447-454 (Pubitemid 46332556)
45. Gordon GJ, Mani M, Mukhopadhyay L, Dong L, Yeap BY, Sugarbaker DJ, Bueno R (2007) Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma. J Pathol 211(4):439-446 (Pubitemid 46332555)
46. Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap B Y, Kindler HL, Salgia R, Sugarbaker DJ, Bueno R (2008) Preclinical studies of the protea-some inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol 61(4):549-558
47. Goto Y, Shinjo K, Kondo Y, Shen L, Toyota M, Suzuki H, Gao W, An B, Fujii M, Murakami H et al (2009) Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res 69(23):9073-9082
48. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57-70 (Pubitemid 30046295)
49. Harvey P, Warn A, Newman P, Perry LJ, Ball RY, Warn RM (1996) Immunoreactivity for hepatocyte growth factor/scatter factor and its receptor, met, in human lung carcinomas and malignant mesotheliomas. J Pathol 180(4): 389-394 (Pubitemid 27014076)
50. Harvey P, Warn A, Dobbin S, Arakaki N, Daikuhara Y, Jaurand MC, Warn RM (1998) Expression of HGF/SF in mesothelioma cell lines and its effects on cell motility, proliferation and morphology. Br J Cancer 77(7):1052-1059 (Pubitemid 28116274)
51. He B, Lee AY, Dadfarmay S, You L, Xu Z, Reguart N, Mazieres J, Mikami I, McCormick F, Jablons DM (2005) Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells. Cancer Res 65(3): 743-748 (Pubitemid 40216431)
52. Hopkins-Donaldson S, Cathomas R, Simoes-Wust AP, Kurtz S, Belyanskaya L, Stahel RA, Zangemeister-Wittke U (2003) Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment. Int J Cancer 106(2):160-166 (Pubitemid 36835166)
53. Hu Q, Akatsuka S, Yamashita Y, Ohara H, Nagai H, Okazaki Y, Takahashi T, Toyokuni S (2010) Homozygous deletion of CDKN2A/2B is a hallmark of iron-induced high-grade rat mesothelioma. Lab Invest: A Journal of Technical Methods and Pathology 90(3): 360-373
54. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S et al (2009) Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461(7264): 614-620
55. Illei PB, Rusch VW, Zakowski MF, Ladanyi M (2003) Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 9(6): 2108-2113 (Pubitemid 36687632)
56. Izzo F, Marra P, Beneduce G, Castello G, Vallone P, De Rosa V, Cremona F, Ensor CM, Holtsberg FW, Bomalaski JS et al (2004) Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol 22(10):1815-1822 (Pubitemid 41095171)
57. Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, Ahmed S, Filiberti R, Paganuzzi M, Puntoni R et al (2006) Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 66(1):352-361 (Pubitemid 43166042)
58. Johnstone RW, Ruefi AA, Lowe SW (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108(2):153-164 (Pubitemid 34161136)
59. Jongsma J, van Montfort E, Vooijs M, Zevenhoven J, Krimpenfort P, van der Valk M, van de Vijver M, Berns A (2008) A conditional mouse model for malignant mesothelioma. Cancer Cell 13(3):261-271 (Pubitemid 351318370)
60. Kawaguchi K, Murakami H, Taniguchi T, Fujii M, Kawata S, Fukui T, Kondo Y, Osada H, Usami N, Yokoi K et al (2009) Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis 30(7):1097-1105
61. Khan O, Fotheringham S, Wood V, Stimson L, Zhang C, Pezzella F, Duvic M, Kerr DJ, La Thangue NB (2010) HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci USA 107(14): 6532-6537
62. Kim KU, Wilson SM, Abayasiriwardana KS, Collins R, Fjellbirkeland L, Xu Z, Jablons DM, Nishimura SL, Broaddus VC (2005) A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. Am J Respir Cell Mol Biol 33(6): 541-548 (Pubitemid 41753129)
63. Kim Y, Ton TV, DeAngelo AB, Morgan K, Devereux TR, Anna C, Collins JB, Paules RS, Crosby LM, Sills RC (2006) Major carcinogenic pathways identified by gene expression analysis of peritoneal mesotheliomas following chemical treatment in F344 rats. Toxicol Appl Pharmacol 214(2):144-151 (Pubitemid 44026611)
64. Kindler HL, Burris HA III, Sandler AB, Oliff IA (2009) A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer. Invest New Drugs 27(1):75-81
65. Kleinberg L, Lie AK, Florenes VA, Nesland JM, Davidson B (2007) Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma. Hum Pathol 38(7): 986-994 (Pubitemid 46899149)
66. Klominek J, Baskin B, Liu Z, Hauzenberger D (1998) Hepatocyte growth factor/scatter factor stimulates chemotaxis and growth of malignant mesothelioma cells through c-met receptor. Int J Cancer 76(2):240-249 (Pubitemid 28180379)
67. Kobayashi N, Toyooka S, Yanai H, Soh J, Fujimoto N, Yamamoto H, Ichihara S, Kimura K, Ichimura K, Sano Y et al (2008) Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma. Lung Cancer (Amsterdam, Netherlands) 62(1):120-125
68. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T et al (2006) Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10(5):375-388 (Pubitemid 44693472)
69. Kratzke RA, Wang X, Wong L, Kratzke MG, Green MR, Vokes EE, Vogelzang NJ, Kindler HL, Kern JA (2008) Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904. J Thorac Oncol 3(4):417-421 (Pubitemid 351489484)
70. Krimpenfort P, Ijpenberg A, Song J Y, van der Valk M, Nawijn M, Zevenhoven J, Berns A (2007) p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a. Nature 448(7156):943-946 (Pubitemid 47312779)
71. Krug LM, Curley T, Schwartz L, Richardson S, Marks P, Chiao J, Kelly WK (2006) Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 7(4): 257-261 (Pubitemid 43280028)
72. Ladanyi M (2005) Implications of P16/CDKN2A deletion in pleural mesotheliomas. Lung Cancer (Amsterdam, Netherlands) 49(Suppl 1):S95-S98 (Pubitemid 40798856)
73. Lecomte C, Andujar P, Renier A, Kheuang L, Abramowski V, Mellottee L, Fleury-Feith J, Zucman-Rossi J, Giovannini M, Jaurand MC (2005) Similar tumor suppressor gene alteration profiles in asbestos-induced murine and human mesothelioma. Cell Cycle (Georgetown, TX) 4(12):1862-1869 (Pubitemid 41827334)
74. Lee AY, He B, You L, Dadfarmay S, Xu Z, Mazieres J, Mikami I, McCormick F, Jablons DM (2004) Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene 23(39):6672-6676 (Pubitemid 39265531)
75. Lee AY, He B, You L, Xu Z, Mazieres J, Reguart N, Mikami I, Batra S, Jablons DM (2004) Dickkopf-1 antagonizes Wnt signaling independent of betacatenin in human mesothelioma. Biochem Biophys Res Commun 323(4):1246-1250 (Pubitemid 39296559)
76. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ (2002) Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2(3):183-192 (Pubitemid 41043974)
77. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X (1997) Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91(4):479-489 (Pubitemid 27508237)
78. Li H, Zhu H, Xu CJ, Yuan J (1998) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94(4):491-501 (Pubitemid 28391865)
79. Li W, You L, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L, Ishii R, Giovannini M, Hanemann CO, Long SB et al (2010) Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell 140(4):477-490
80. Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L, Williams S, Wiegmans AP, Dear AE, Scott CL et al (2007) Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci USA 104(19):8071-8076 (Pubitemid 47185877)
81. Lu J, Ma Z, Hsieh JC, Fan CW, Chen B, Longgood JC, Williams NS, Amatruda JF, Lum L, Chen C (2009) Structure-activity relationship studies of small-molecule inhibitors of Wnt response. Bioorg Med Chem Lett 19(14): 3825-3827
82. Martins LM, Iaccarino I, Tenev T, Gschmeissner S, Totty NF, Lemoine NR, Savopoulos J, Gray CW, Creasy CL, Dingwall C et al (2002) The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. J Biol Chem 277(1):439-444 (Pubitemid 34952077)
83. Mazieres J, You L, He B, Xu Z, Twogood S, Lee AY, Reguart N, Batra S, Mikami I, Jablons DM (2005) Wnt2 as a new therapeutic target in malignant pleural mesothelioma. Int J Cancer 117(2):326-332 (Pubitemid 41377454)
84. Meijerink JP, Mensink EJ, Wang K, Sedlak TW, Sloetjes AW, de Witte T, Waksman G, Korsmeyer SJ (1998) Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood 91(8):2991-2997 (Pubitemid 28227551)
85. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, Waldman T, Lord CJ, Ashworth A (2009) Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 1(6-7):315-322
86. Mitsiades CS, Poulaki V, McMullan C, Negri J, Fanourakis G, Goudopoulou A, Richon VM, Marks PA, Mitsiades N (2005) Novel histone deacetylase inhibitors in the treatment of thyroid cancer. Clin Cancer Res 11(10):3958-3965 (Pubitemid 40685618)
87. Mohiuddin I, Cao X, Ozvaran MK, Zumstein L, Chada S, Smythe WR (2002) Phosphatase and tensin analog gene overexpression engenders cellular death in human malignant mesothelioma cells via inhibition of AKT phosphorylation. Ann Surg Oncol 9(3):310-316 (Pubitemid 34298638)
88. Moye-Rowley WS, Harshman KD, Parker CS (1989) Yeast YAP1 encodes a novel form of the jun family of transcriptional activator proteins. Genes Dev 3(3):283-292
89. Mukohara T, Civiello G, Davis IJ, Taffaro ML, Christensen J, Fisher DE, Johnson BE, Janne PA (2005) Inhibition of the met receptor in mesothelioma. Clin Cancer Res 11(22):8122-8130 (Pubitemid 41698757)
90. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffdi C, Bretz JD, Zhang M, Gentz R et al (1996) FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85(6): 817-827 (Pubitemid 26193033)
91. Neragi-Miandoab S, Sugarbaker DJ (2009) Chromosomal deletion in patients with malignant pleural mesothelioma. Interact Cardiovasc Thorac Surg 9(1):42-44
92. Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR, Goulet D, Viallet J, Belec L, Billot X et al (2007) Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 104(49):19512-19517
93. Nikiforov MA, Riblett M, Tang WH, Gratchouck V, Zhuang D, Fernandez Y, Verhaegen M, Varambally S, Chinnaiyan AM, Jakubowiak AJ et al (2007) Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc Natl Acad Sci USA 104(49):19488-19493
94. Nikrad M, Johnson T, Puthalalath H, Coultas L, Adams J, Kraft AS (2005) The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther 4(3):443-449 (Pubitemid 40443929)
95. O'Connor L, Strasser A, O'Reilly LA, Hausmann G, Adams JM, Cory S, Huang DC (1998) Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J 17(2):384-395 (Pubitemid 28045479)
96. O'Kane SL, Pound RJ, Campbell A, Chaudhuri N, Lind MJ, Cawkwell L (2006) Expression of bcl-2 family members in malignant pleural mesothelioma. Acta Oncol (Stockholm, Sweden) 45(4):449-453 (Pubitemid 43884613)
97. Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, Scheffer GL, Debipersad K, Vojtekova K, Lemos C et al (2008) Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 112(6):2489-2499
98. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ et al (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435(7042):677-681 (Pubitemid 40825512)
99. Oltvai ZN, Milliman CL, Korsmeyer SJ (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74(4):609-619 (Pubitemid 23259742)
100. Onofire FB, Onofre AS, Pomjanski N, Buckstegge B, Grote HJ, Bocking A (2008) 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis. Cancer 114(3):204-215 (Pubitemid 351969240)
101. Opitz I, Soltermann A, Abaecherli M, Hinterberger M, Probst-Hensch N, Stahel R, Moch H, Weder W (2008) PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg 33(3):502-506
102. Papp T, Schipper H, Pemsel H, Bastrop R, Muller KM, Wiethege T, Weiss DG, Dopp E, Schiffmann D, Rahman Q (2001) Mutational analysis of N-ras, p53, p16INK4a, p14ARF and CDK4 genes in primary human malignant mesotheliomas. Int J Oncol 18(2):425-433
103. * is linked to the prognosis of malignant pleural mesothelioma. Cancer Res 70(5): 1916-1924
104. Pespeni MH, Hodnett M, Abayasiriwardana KS, Roux J, Howard M, Broaddus VC, Pittet JF (2007) Sensitization of mesothelioma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by heat stress via the inhibition of the 3-phosphoinositide-dependent kinase 1/Akt pathway. Cancer Res 67(6):2865-2871 (Pubitemid 46548977)
105. Pinton G, Brunelli E, Murer B, Puntoni R, Puntoni M, Fennell DA, Gaudino G, Mutti L, Moro L (2009) Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res 69(11):4598-4604
106. Poulikakos PI, Xiao GH, Gallagher R, Jablonski S, Jhanwar SC, Testa JR (2006) Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene 25(44):5960-5968 (Pubitemid 44477290)
107. Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, Bennett F, Pollock PM, Trent JM, Hendrix MJ et al (2005) Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 65(14):6282-6293 (Pubitemid 40994414)
108. Ramalingam SS, Belani CP, Ruel C, Frankel P, Gitlitz B, Koczywas M, Espinoza-Delgado I, Gandara D (2009) Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol 4(1): 97-101
109. Ramos-Nino ME, Scapoli L, Martinelli M, Land S, Mossman BT (2003) Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma. Cancer Res 63(13):3539-3545 (Pubitemid 36793033)
110. Ramos-Nino ME, Blumen SR, Pass H, Mossman BT (2007) Fra-1 governs cell migration via modulation of CD44 expression in human mesotheliomas. Mol Cancer 6:81
111. Ramos-Nino ME, Blumen SR, Sabo-Attwood T, Pass H, Carbone M, Testa JR, Altomare DA, Mossman BT (2008) HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway. Am J Respir Cell Mol Biol 38(2): 209-217 (Pubitemid 351162843)
112. Rippo MR, Moretti S, Vescovi S, Tomasetti M, Orecchia S, Amici G, Catalano A, Procopio A (2004) FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells. Oncogene 23(47): 7753-7760 (Pubitemid 39457025)
113. Sartore-Bianchi A, Gasparri F, Galvani A, Nici L, Darnowski JW, Barbone D, Fennell DA, Gaudino G, Porta C, Mutti L (2007) Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res 13(19):5942-5951 (Pubitemid 47583922)
114. Sealy L, Chalkley R (1978) The effect of sodium butyrate on histone modification. Cell 14(1):115-121 (Pubitemid 8340439)
115. Sedlak TW, Oltvai ZN, Yang E, Wang K, Boise LH, Thompson CB, Korsmeyer SJ (1995) Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci USA 92(17):7834-7838
116. Sekido Y, Pass HI, Bader S, Mew DJ, Christman MF, Gazdar AF, Minna JD (1995) Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 55(6):1227-1231
117. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, Yin Y (2007) Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128(1):157-170 (Pubitemid 46048887)
118. Shigemitsu K, Sekido Y, Usami N, Mori S, Sato M, Horio Y, Hasegawa Y, Bader SA, Gazdar AF, Minna JD et al (2001) Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion. Oncogene 20(31):4249-4257 (Pubitemid 32762199)
119. Soini Y, Kinnula V, Kaarteenaho-Wiik R, Kurttila E, Linnainmaa K, Paakko P (1999) Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma. Clin Cancer Res 5(11):3508-3515
120. Sumi K, Matsuyama S, Kitajima Y, Miyazaki K (2004) Loss of estrogen receptor beta expression at cancer front correlates with tumor progression and poor prognosis of gallbladder cancer. Oncol Rep 12(5):979-984
121. Sun X, Gulyas M, Hjerpe A, Dobra K (2006) Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells. Cancer Lett 232(2):161-169 (Pubitemid 43170965)
122. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler M et al (1999) Molecular characterization of mitochondrial apoptosisinducing factor. Nature 397(6718):441-446
123. Symanowski J, Vogelzang N, Zawel L, Atadja P, Pass H, Sharma S (2009) A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL. J Thorac Oncol 4(2):149-160
124. Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, Crook T, Grimshaw MJ, Steele JP, Rudd RM, Balkwill FR et al (2006) In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res 12(23):7126-7131 (Pubitemid 44974513)
125. Taguchi T, Jhanwar SC, Siegfried JM, Keller SM, Testa JR (1993) Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res 53(18):4349-4355 (Pubitemid 24146789)
126. Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB (2006) Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem 281(9):5612-5622 (Pubitemid 43847658)
127. Tartaglia LA, Ayres TM, Wong GH, Goeddel DV (1993) A novel domain within the 55 kd TNF receptor signals cell death. Cell 74(5): 845-853 (Pubitemid 23270604)
128. Thirkettle I, Harvey P, Hasleton PS, Ball RY, Warn RM (2000) Immunoreactivity for cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas. Histopathology 36(6):522-528 (Pubitemid 30348777)
129. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM (1984) Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science (New York 226(4678):1097-1099 (Pubitemid 15217831)
130. Uematsu K, Kanazawa S, You L, He B, Xu Z, Li K, Peterlin BM, McCormick F, Jablons DM (2003) Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin. Cancer Res 63(15):4547-4551 (Pubitemid 36951028)
131. Uematsu K, Seki N, Seto T, Isoe C, Tsukamoto H, Mikami I, You L, He B, Xu Z, Jablons DM et al (2007) Targeting the Wnt signaling pathway with dishevelled and cisplatin synergistically suppresses mesothelioma cell growth. Anticancer Res 27(6B):4239-4242
132. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S et al (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10(5):389-399 (Pubitemid 44711953)
133. Vandermeers F, Hubert P, Delvenne P, Mascaux C, Grigoriu B, Burny A, Scherpereel A, Willems L (2009) Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin Cancer Res 15(8): 2818-2828
134. Velcheti V, Kasai Y, Viswanathan AK, Ritter J, Govindan R (2009) Absence of mutations in the epidermal growth factor receptor (EGFR) kinase domain in patients with mesothelioma. J Thorac Oncol 4(4):559
135. Vivo C, Liu W, Broaddus VC (2003) c-Jun N-terminal kinase contributes to apoptotic synergy induced by tumor necrosis factor-related apoptosis-inducing ligand plus DNA damage in chemoresistant, p53 inactive mesothelioma cells. J Biol Chem 278(28):25461-25467 (Pubitemid 36835297)
136. Wang K, Yin XM, Chao DT, Milliman CL, Korsmeyer SJ (1996) BID: a novel BH3 domain-only death agonist. Genes Dev 10(22): 2859-2869 (Pubitemid 26394246)
137. Wang L, Du F, Wang X (2008) TNF-alpha induces two distinct caspase-8 activation pathways. Cell 133(4):693-703 (Pubitemid 351636305)
138. Wang Y, Rishi AK, Puliyappadamba VT, Sharma S, Yang H, Tarca A, Ping Dou Q, Lonardo F, Ruckdeschel JC, Pass HI et al (2009) Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines. Cancer Chemother Pharmacol 10:1235-1244
139. Wang Q, Mora-Jensen H, Weniger MA, Perez-Galan P, Wolford C, Hai T, Ron D, Chen W, Trenkle W, Wiestner A et al (2009) ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc Natl Acad Sci USA 106(7):2200-2205
140. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB, Korsmeyer SJ (2001) Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science (New York) 292(5517):727-730 (Pubitemid 32385543)
141. Wilson TR, Redmond KM, McLaughlin KM, Crawford N, Gately K, O'Byrne K, Le-Clorrenec C, Holohan C, Fennell DA, Johnston PG et al (2009) Procaspase 8 overex-pression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing. Cell Death Differ 16(10):1352-1361
142. Wong L, Zhou J, Anderson D, Kratzke RA (2002) Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer (Amsterdam, Netherlands) 38(2): 131-136 (Pubitemid 35154376)
143. www.cancer.gov: Suberoylanilide hydroxamic acid (Vorinostat, MK0683) versus placebo in advanced malignant pleural mesothelioma. In www.http://clinicaltrials.goc/ct2/show/NCT00128102.
144. Xia C, Xu Z, Yuan X, Uematsu K, You L, Li K, Li L, McCormick F, Jablons DM (2002) Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther 1(9):687-694
145. Xio S, Li D, Vijg J, Sugarbaker DJ, Corson JM, Fletcher JA (1995) Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 11(3):511-515
146. Yin XM, Oltvai ZN, Korsmeyer SJ (1994) BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 369(6478):321-323 (Pubitemid 24159542)
147. Yin C, Knudson CM, Korsmeyer SJ, Van Dyke T (1997) Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385 (6617):637-640 (Pubitemid 27087577)
148. Yokoyama T, Osada H, Murakami H, Tatematsu Y, Taniguchi T, Kondo Y, Yatabe Y, Hasegawa Y, Shimokata K, Horio Y et al (2008) YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. Carcinogenesis 29(11):2139-2146
149. Yoshida H, Kong YY, Yoshida R, Elia AJ, Hakem A, Hakem R, Penninger JM, Mak TW (1998) Apaf1 is required for mitochondrial pathways of apoptosis and brain development. Cell 94(6):739-750 (Pubitemid 28436006)
150. You L, He B, Uematsu K, Xu Z, Mazieres J, Lee A, McCormick F, Jablons DM (2004) Inhibition of Wnt-1 signaling induces apoptosis in beta-catenin-deficient mesothelioma cells. Cancer Res 64(10):3474-3478 (Pubitemid 38657920)
151. Yuan BZ, Chapman JA, Reynolds SH (2008) Proteasome inhibitor MG132 induces apoptosis and inhibits invasion of human malignant pleural mesothelioma cells. Transl Oncol 1(3): 129-140
152. Zaffaroni N, Costa A, Pennati M, De Marco C, Affini E, Madeo M, Erdas R, Cabras A, Kusamura S, Baratti D et al (2007) Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma. Cell Oncol 29(6):453-466 (Pubitemid 350136500)
153. Zimmerman RL, Fogt F (2001) Evaluation of the c-Met immunostain to detect malignant cells in body cavity effusions. Oncol Rep 8(6):1347-1350 (Pubitemid 33758744)